Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of HRS-7085 in healthy subjects
NCT06175949Phase 1Not yet recruiting
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Start
- Dec 2023
- Primary completion
- Jun 2024
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial in inflammatory bowel disease (IBD) comparing HRS-7085 with Placebo (2 arms). Primary endpoint: Adverse events at 20 days. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
HRS-7085
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT06175949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06175949.